乳腺癌组织中HER2、ERα、ERβ、PR的表达及其相关性分析

目的探讨雌激素受体α（ERα）、雌激素受体β（ERβ）、孕激素受体（PR）、人类表皮生长因子受体2（HER2）在乳腺癌组织中的表达及其与TNM分期和腋窝淋巴结状况的关系。方法随机选择我院在2004年12月至2007年12月收治的HER2高表达（＋＋＋）51例与无表达（-）53例乳腺浸润性导管癌病例，分别检测乳腺癌组织的ERα、ERβ、PR的表达水平，分析其与TNM分期、腋窝淋巴结转移等临床指标的相关性。结果104例乳腺癌患者，TNM分期为I期的占14．42％，Ⅱ期占62．50％，Ⅲ期占19．23％，Ⅳ期占3．85％；HER2阳性的淋巴结转移率为41．18％，HER2阴性的转移率为47．5％；ERα、ERβ、PR的阳性表达率分别为52．88％、63．46％、73．08％。ERβ与ERα、PR的表达呈正相关（P〈0．01），与HER2的表达负相关（P〈0．01）；ERα与PR的表达正相关（P〈0．01），与HER2负相关（P〈0．01），PR与HER2的表达负相关（P〈0．05）；ERα、ERβ、PR、HER2的表达与淋巴结转移情况及TNM分期无显著相关性。结论HER2作为乳腺癌预后不良的重要指标与作为乳腺癌预后良好的重要指标ERα、ERβ、PR的表达呈负相关，与TNM分期及腋窝淋巴结转移状态未显示明显相关性。

Expression of HER2, ERα, ERβ and PR in breast cancer and their clinical significance

Objective Investigate the expression of estrogen receptor α（ER α）, estrogen receptor β（ER β）, progesterone receptor （PR）, human epithelial growth factor receptor 2 （HER2） in breast cancer and their relationship with TNM stage and lymph node metastasis. Methods 51 HER2 （＋＋＋） cases and 53 HER2（-） cases were randomly selected in our hospital from Dec 2004 to Dec 2007, and were detected for the expressions of ERα ER β and PR respectively, then their relationship with TNM stage and lymph node metastasis were analyzed. Results Of all of 104 cases of breast cancer, the ratios of different stages were 14.42% （stage 1）, 62.50% （stage Ⅱ）, 19.23% （stage Ⅲ） and 3.85% （stage Ⅳ） respectively. The positive rate of lymph node metastasis in the HER2（＋＋＋） patients was 41.18%, and in HER2（-） patients was 47.5%. The positive rates of ERα,ERβ, and PR were 52.88%, 63.46%, 73.08% respectively. The expression of ERβ was positively correlated with ERα and PR （P〈0.01） and negatively correlated with HER2（P〈0.01）. The expression of ERα was positively correlated with PR （P〈0.01） and negatively correlated with HER2（P〈0.01）. The expression of PR was negatively correlated with HER2（P〈0.05）. The expression of ERα, ERβ, PR and HER2 were irrelevant with TNM stages and lymph node metastasis. Conclusion As the good prognostic markers, ERα, ERβ, PR have negative correlation with the expression of HER2, an unfavorable prognostic marker, which shows no correlation with TNM stages and lymph node metastasis.